Reply to research letter

In response to: “Reply to research letter”

“…To the Editor: We appreciate the interest of Rivera-Oyola et al 1 in our meta-estimate evaluating the risk of respiratory tract infections (RTIs) and symptoms in patients with psoriasis treated with biologics that inhibit the interleukin (IL) 17 pathway. 2 The authors make a cogent case for the importance of not cherrypicking data when evaluating drug safety by selecting a few examples in which perhaps patients treated with IL-17 inhibitors have a lower risk of RTIs compared with placebo.…”